{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:21:49Z","timestamp":1787304109285,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"vor","delay-in-days":247,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jlr.org"],"crossmark-restriction":true},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1194\/jlr.ra119000419","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T20:44:17Z","timestamp":1576529057000},"page":"365-375","update-policy":"https:\/\/doi.org\/10.1194\/jlr.f110.005975","source":"Crossref","is-referenced-by-count":65,"title":["Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9657-871X","authenticated-orcid":false,"given":"Marianne G.","family":"Pouwer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsbet J.","family":"Pieterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Worms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanda","family":"Keijzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Wouter","family":"Jukema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Gromada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Gusarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans M.G.","family":"Princen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1194\/jlr.RA119000419_bib1","unstructured":"World Health Organization. 2016. Hearts: technical package for cardiovascular disease management in primary health care. Accessed November 21, 2019, at http:\/\/www.who.int\/cardiovascular_diseases\/publications\/en\/."},{"key":"10.1194\/jlr.RA119000419_bib2","first-page":"e1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation."},{"key":"10.1194\/jlr.RA119000419_bib3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA."},{"key":"10.1194\/jlr.RA119000419_bib4","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1093\/eurheartj\/eht260","article-title":"Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy","volume":"34","author":"Puri","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1194\/jlr.RA119000419_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2018.01.012","article-title":"Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies","volume":"269","author":"Gragnano","year":"2018","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.RA119000419_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2014.02.007","article-title":"A systematic review of the time course of atherosclerotic plaque regression","volume":"234","author":"Noyes","year":"2014","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.RA119000419_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1471-2261-14-60","article-title":"Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound","volume":"14","author":"Gao","year":"2014","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1194\/jlr.RA119000419_bib8","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet."},{"key":"10.1194\/jlr.RA119000419_bib9","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/er.2018-00184","article-title":"The forgotten lipids: Triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk","volume":"40","author":"Sandesara","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1194\/jlr.RA119000419_bib10","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/MOL.0000000000000237","article-title":"Non-high-density lipoprotein cholesterol: current status as cardiovascular marker","volume":"26","author":"Verbeek","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1194\/jlr.RA119000419_bib11","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA."},{"key":"10.1194\/jlr.RA119000419_bib12","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2010.02.026","article-title":"Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome","volume":"55","author":"Nicholls","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.RA119000419_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12916-015-0459-4","article-title":"Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies","volume":"13","author":"Banach","year":"2015","journal-title":"BMC Med."},{"key":"10.1194\/jlr.RA119000419_bib14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/MOL.0000000000000493","article-title":"Regression of atherosclerosis: lessons learned from genetically modified mouse models","volume":"29","author":"Burke","year":"2018","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1194\/jlr.RA119000419_bib15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.toxrep.2016.02.002","article-title":"Comment on \u201cHypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice\u201d by Rebholz S.L. et al. 2016. Toxicol. Rep. 3: 46\u201354","volume":"3","author":"Princen","year":"2016","journal-title":"Toxicol. Rep."},{"key":"10.1194\/jlr.RA119000419_bib16","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1161\/hq1001.096651","article-title":"Raman spectroscopic evaluation of the effects of diet and lipid-lowering therapy on atherosclerotic plaque development in mice","volume":"21","author":"van De Poll","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.RA119000419_bib17","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1194\/jlr.M051326","article-title":"Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin","volume":"55","author":"K\u00fchnast","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.RA119000419_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.RA119000419_bib19","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/ATVBAHA.107.142570","article-title":"Mouse models for atherosclerosis and pharmaceutical modifiers","volume":"27","author":"Zadelaar","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.RA119000419_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejphar.2015.03.089","article-title":"Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C\/LDL-C-lowering versus HDL-C-raising: a systematic review and meta-analysis of relevant preclinical studies and clinical trials","volume":"763","author":"K\u00fchnast","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1194\/jlr.RA119000419_bib21","doi-asserted-by":"crossref","first-page":"9727952","DOI":"10.1155\/2019\/9727952","article-title":"The APOE*3-Leiden.heterozygous glucokinase knockout mouse as novel translational disease model for type 2 diabetes, dyslipidemia and diabetic atherosclerosis","volume":"2019","author":"Pouwer","year":"2019","journal-title":"J. Diabetes Res."},{"key":"10.1194\/jlr.RA119000419_bib22","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1172\/JCI115349","article-title":"Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree","volume":"88","author":"de Knijff","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.RA119000419_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00005344-200307000-00010","article-title":"Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice","volume":"42","author":"Delsing","year":"2003","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1194\/jlr.RA119000419_bib24","doi-asserted-by":"crossref","first-page":"25168","DOI":"10.1074\/jbc.M110.123992","article-title":"Fenofibrate increases very low density lipoprotein-triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice","volume":"285","author":"Bijland","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.RA119000419_bib25","doi-asserted-by":"crossref","first-page":"e66467","DOI":"10.1371\/journal.pone.0066467","article-title":"Niacin reduces atherosclerosis development in APOE*3Leiden.CETP mice mainly by reducing nonHDL-cholesterol","volume":"8","author":"K\u00fchnast","year":"2013","journal-title":"PLoS One."},{"key":"10.1194\/jlr.RA119000419_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/eurheartj\/ehu319","article-title":"Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDLcholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin","volume":"36","author":"K\u00fchnast","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1194\/jlr.RA119000419_bib27","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1194\/jlr.M053207","article-title":"PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE","volume":"55","author":"Ason","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.RA119000419_bib28","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.RA119000419_bib29","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1194\/jlr.M054890","article-title":"ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys","volume":"56","author":"Gusarova","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.RA119000419_bib30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.RA119000419_bib31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.atherosclerosis.2007.08.001","article-title":"Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice","volume":"197","author":"de Haan","year":"2008","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.RA119000419_bib32","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1172\/JCI118532","article-title":"Modulation of very low density lipoprotein production and clearance contributes to age- and gender-dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice","volume":"97","author":"van Vlijmen","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.RA119000419_bib33","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.RA119000419_bib34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1476-5381.2008.00109.x","article-title":"The dual PPAR\u03b1\/\u03b3 agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3-Leiden.CETP transgenic mice","volume":"156","author":"van der Hoorn","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1194\/jlr.RA119000419_bib35","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","article-title":"The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice","volume":"38","author":"Landlinger","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1194\/jlr.RA119000419_bib36","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.CIR.92.5.1355","article-title":"A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association","volume":"92","author":"Stary","year":"1995","journal-title":"Circulation."},{"key":"10.1194\/jlr.RA119000419_bib37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/HJH.0b013e32834ddd8e","article-title":"Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin","volume":"30","author":"K\u00fchnast","year":"2012","journal-title":"J. Hypertens."},{"key":"10.1194\/jlr.RA119000419_bib38","doi-asserted-by":"crossref","first-page":"26P","DOI":"10.1016\/j.amjcard.2006.09.017","article-title":"Plaque stabilization: can we turn theory into evidence?","volume":"98","author":"Libby","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1194\/jlr.RA119000419_bib39","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/CIRCINTERVENTIONS.109.922146","article-title":"The high-risk thin-cap fibroatheroma: a new kid on the block","volume":"2","author":"Moreno","year":"2009","journal-title":"Circ. Cardiovasc. Interv."},{"key":"10.1194\/jlr.RA119000419_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pcad.2008.09.001","article-title":"Atherosclerotic plaque stability: what determines the fate of a plaque?","volume":"51","author":"Halvorsen","year":"2008","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1194\/jlr.RA119000419_bib41","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1161\/01.ATV.0000238348.05028.14","article-title":"Fenofibrate reduces atherogenesis in APOE*3Leiden mice: Evidence for multiple anti-atherogenic effects besides lowering plasma cholesterol","volume":"26","author":"Kooistra","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.RA119000419_bib42","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1161\/01.CIR.103.13.1778","article-title":"The acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in apoE*3Leiden mice","volume":"103","author":"Delsing","year":"2001","journal-title":"Circulation."},{"key":"10.1194\/jlr.RA119000419_bib43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fcvm.2018.00032","article-title":"Insights from pre-clinical and clinical studies on the role of innate inflammation in atherosclerosis regression","volume":"5","author":"Rahman","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1194\/jlr.RA119000419_bib44","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.RA119000419_bib45","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of acute coronary syndromes and their implications for therapy","volume":"368","author":"Libby","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.RA119000419_bib46","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nri3520","article-title":"Macrophages in atherosclerosis: a dynamic balance","volume":"13","author":"Moore","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1194\/jlr.RA119000419_bib47","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1161\/CIRCULATIONAHA.107.745091","article-title":"Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice","volume":"117","author":"Combadi\u00e8re","year":"2008","journal-title":"Circulation."},{"key":"10.1194\/jlr.RA119000419_bib48","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/nm.3258","article-title":"Local proliferation dominates lesional macrophage accumulation in atherosclerosis","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat. Med."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520435205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520435205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1194\/jlr.RA119000419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T20:05:10Z","timestamp":1638043510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227520435205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0022227520435205"],"URL":"https:\/\/doi.org\/10.1194\/jlr.ra119000419","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}